Abstract
OBJECTIVE Depression is a common co-morbidity of type 2 diabetes. However, the causality and underlying mechanisms remain unclear.
RESEARCH DESIGN AND METHODS We applied bi-directional Mendelian randomization (MR) to assess causality between type 2 diabetes and self-reported depression. Using the UK biobank, we performed 1) GWAS, separately, and 2) multi-phenotype GWAS (MP-GWAS) of type 2 diabetes (cases=19,344, controls=463,641) and depression, using two depression definitions–clinically diagnosed major depressive disorder (MDD, cases=5,262, controls=86,275) and self-reported depressive symptoms (PHQ-9, n=153,079). The FinnGen study was used for replication for MDD (n=23,424) and type 2 diabetes (n=32,469). Based on the results, we analyzed expression quantitative trait loci (eQTL) data from public databases to identify target genes in relevant tissues.
RESULTS MR demonstrated a significant causal effect of depression on type 2 diabetes (OR=1.18[1.06-1.32], p=0.0024), but not in the reverse direction. GWAS of type 2 diabetes and depressive symptoms did not identify any shared loci between them, whereas MP-GWAS identified seven shared loci mapped to TCF7L2, CDKAL1, IGF2BP2, SPRY2, CCND2-AS1, IRS1, CDKN2B-AS1. MDD did not yield genome-wide significant loci in either GWAS or MP-GWAS. We found that most MP-GWAS loci had an eQTL, including SNPs implicating the cell cycle gene CCND2 in pancreatic islets and brain, and key insulin signaling gene IRS1 in adipose tissue, suggesting a multi-tissue and pleiotropic underlying mechanism.
CONCLUSION Our study reveals the complexity in the depression-diabetes relationship and our results have important implications for a more efficient prevention of type 2 diabetes from early adulthood when depressive symptoms usually occur.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research has been conducted using the UK Biobank Resource under Application Number 35327. This research was in part funded by the Diabetes UK (BDA number: 20/0006307), the European Union Horizon 2020 research and innovation programme (LONGITOOLS, H2020-SC1-2019-874739), Agence Nationale de la Recherche (PreciDIAB, ANR-18-IBHU-0001), by the European Union through the Fonds europeen de developpement regional (FEDER), by the Conseil Regional des Hauts-de-France (Hauts-de-France Regional Council) and by the Metropole Europeenne de Lille (MEL, European Metropolis of Lille).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We used the publicly available UK Biobank (https://www.ukbiobank.ac.uk/) and FinnGen (https://www.finngen.fi/en) datasets
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
